Bausch + Lomb Corporation

Bausch + Lomb Corporation (NYSE:BLCO) is a global eye health company with roots dating back to 1853, making it one of the oldest and most established names in vision care. Originally founded as an optical goods company in Rochester, New York, Bausch + Lomb has evolved into a comprehensive eye health enterprise. The company went public in May 2022 following a spinoff from Bausch Health Companies, establishing itself as an independent publicly traded entity focused exclusively on eye care products and services. Today, the company operates from its headquarters in Vaughan, Canada, and serves customers worldwide across three distinct business segments covering the entire spectrum of eye health needs.

Over the past several years, Bausch + Lomb has executed a strategic transformation focused on accelerating growth through innovation and market expansion. The company completed its independence through a 2022 IPO, establishing itself as a pure-play eye health company under new leadership with Brent Saunders as CEO. Key strategic developments include aggressive expansion in the dry eye treatment market through the acquisition and launch of XIIDRA and the development of MIEBO, building a dry eye portfolio approaching $1 billion in annual revenue. The company has invested heavily in next-generation contact lens technology, particularly Daily SiHy lenses which have shown exceptional growth of 42-79% year-over-year, and is developing innovative biomimetic contact lenses and myopia control solutions. Digital transformation initiatives have been central to recent strategy, including the launch of Opal, an e-commerce marketplace for contact lenses, and Glimpse, an AI-driven sales platform. The company has also invested in direct-to-consumer marketing campaigns for pharmaceutical products to drive patient awareness and prescription demand. Manufacturing and operational excellence programs have focused on supply chain optimization, with new production lines installed in Milan and Berlin, and deployment of AI technology in contact lens manufacturing to improve yields. The company has also strengthened its surgical portfolio through premium IOL launches including enVista Envy trifocal lenses and is preparing for the approval of ELIOS MIGS glaucoma products. Recent challenges include managing a voluntary recall of enVista intraocular lenses due to potential complications, though the company successfully returned to market within a month through collaboration with leading surgeons.